3 Stocks Pushing The Health Care Sector Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 29 points (-0.2%) at 16,877 as of Thursday, June 19, 2014, 1:00 PM ET. The NYSE advances/declines ratio sits at 1,663 issues advancing vs. 1,297 declining with 187 unchanged.

The Health Care sector currently sits down 0.3% versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the sector include Regeneron Pharmaceuticals ( REGN), down 2.0%, Shire ( SHPG), down 1.6%, Vertex Pharmaceuticals ( VRTX), down 1.2%, Valeant Pharmaceuticals International ( VRX), down 1.2% and Actavis ( ACT), down 0.9%. Top gainers within the sector include Medtronic ( MDT), up 1.5%, WellPoint ( WLP), up 1.1%, UnitedHealth Group ( UNH), up 1.0%, Humana ( HUM), up 0.9% and Sanofi ( SNY), up 1.1%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Alexion Pharmaceuticals ( ALXN) is one of the companies pushing the Health Care sector lower today. As of noon trading, Alexion Pharmaceuticals is down $2.01 (-1.2%) to $158.42 on light volume. Thus far, 463,572 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $157.84-$160.92 after having opened the day at $160.91 as compared to the previous trading day's close of $160.43.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $31.7 billion and is part of the drugs industry. Shares are up 20.5% year-to-date as of the close of trading on Wednesday. Currently there are 13 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, increase in net income and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Alexion Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, AbbVie ( ABBV) is down $0.35 (-0.6%) to $54.22 on light volume. Thus far, 1.6 million shares of AbbVie exchanged hands as compared to its average daily volume of 5.6 million shares. The stock has ranged in price between $54.08-$54.81 after having opened the day at $54.14 as compared to the previous trading day's close of $54.57.

AbbVie Inc., a research-based biopharmaceutical company, is engaged in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. AbbVie has a market cap of $86.3 billion and is part of the drugs industry. Shares are up 3.3% year-to-date as of the close of trading on Wednesday. Currently there are 5 analysts that rate AbbVie a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates AbbVie as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, revenue growth and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and generally higher debt management risk. Get the full AbbVie Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Pfizer ( PFE) is down $0.15 (-0.5%) to $29.56 on light volume. Thus far, 7.5 million shares of Pfizer exchanged hands as compared to its average daily volume of 29.7 million shares. The stock has ranged in price between $29.52-$29.71 after having opened the day at $29.70 as compared to the previous trading day's close of $29.71.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Its product portfolio includes medicines and vaccines, as well as various consumer healthcare products. Pfizer has a market cap of $188.0 billion and is part of the drugs industry. Shares are down 3.0% year-to-date as of the close of trading on Wednesday. Currently there are 8 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pfizer Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Dow Falls Sharply as Apple's Slump Offsets Gains in General Electric

Dow Falls Sharply as Apple's Slump Offsets Gains in General Electric

Video: How to Select Mutual Funds in Your 401(k)

Video: How to Select Mutual Funds in Your 401(k)

Nucor Is Waiting to See if Steel Tariffs Will Be Implemented, Jim Cramer Says

Nucor Is Waiting to See if Steel Tariffs Will Be Implemented, Jim Cramer Says

Tesla Faces Investigation After Subcontractor Is Injured on the Job

Tesla Faces Investigation After Subcontractor Is Injured on the Job

Video: Jim Cramer on Apple, Amazon, Alphabet and Nucor

Video: Jim Cramer on Apple, Amazon, Alphabet and Nucor